Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Breast cancer

High-dose fulvestrant is a safe and effective therapy for breast cancer

Nature Reviews Clinical Oncology volume 7, page 673 (2010)Cite this article

Subjects

Access through your institution
Buy or subscribe

Fulvestrant is an estrogen-receptor targeting therapy that is used for the treatment of advanced-stage breast cancer in postmenopausal women with endocrine-sensitive cancer. The current approved dose is 250 mg but observational and phase II evidence indicated that a higher dose might be more effective.

The observations led to a hypothesis-driven phase III, randomized clinical trial conducted by the Comparison of Faslodex in Recurrent or Metastatic Breast Cancer (CONFIRM) investigators. They assessed two doses of fulvestrant (250 mg and 500 mg) in 736 women with advanced disease who had progressed on first-line endocrine therapy.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

ORIGINAL RESEARCH PAPER

  1. Di Leo, A. et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J. Clin. Oncol. 28, 4594–4600 (2010)

    Article  CAS  Google Scholar 

Download references

Authors
  1. Rebecca Kirk
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kirk, R. High-dose fulvestrant is a safe and effective therapy for breast cancer. Nat Rev Clin Oncol 7, 673 (2010). https://doi.org/10.1038/nrclinonc.2010.181

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrclinonc.2010.181

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer